The city of Los Angeles, California, currently has 4 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies.
HEALEY ALS Platform Trial - Master Protocol
Recruiting
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: Kaiser Permanente Los Angeles Medical Center, Los Angeles, California +2 locations
Conditions: Amyotrophic Lateral Sclerosis
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: University of California, Los Angeles, Los Angeles, California
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
Recruiting
The investigator is examining the safety of transplanting cells, that have been engineered to produce a growth factor, into the motor cortex (brain) of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neural cell. The growth factor is called glial cell line-derived... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/05/2024
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Amyotrophic Lateral Sclerosis
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
Recruiting
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 81 years
Trial Updated:
04/14/2023
Locations: University of Southern California, Los Angeles, California
Conditions: Amyotrophic Lateral Sclerosis